Fig. 3From: Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisForest plots for predictive analyses of BRAF mutations in trials comparing experimental arm with control arm—a, b progression-free survival, c, d overall survival and e, f objective response rate. PFS, progression-free survival; OS overall survival; ORR, objective response rateBack to article page